基于疾病表型的系统性红斑狼疮先进疗法应用:单中心回顾性分析
该单中心横断面分析对327例SLE患者按10项血清学特征进行层次聚类,识别出4个血清学聚类。抗Sm/RNP聚类表现为最严重表型,需多种免疫抑制剂且生物制剂使用率最高;晚发型SLE生物制剂和传统免疫抑制剂使用显著更少,但累积器官损伤更重。结论支持血清学指导的分层管理。
要点
- 抗Sm/RNP聚类与最严重表型相关,生物制剂使用率最高。
- 晚发型SLE治疗强度更低但累积器官损伤更重。
- 血清学指导的分层可能优化SLE先进疗法的应用。
核心结论
- 抗Sm/RNP特征识别出严重难治表型,可能需要强化生物制剂治疗。
- 晚发型SLE是沉默风险组,较低治疗强度与较高损伤累积相关,提示当前管理策略可能不足。
研究设计与样本
- 单中心327例SLE患者的横断面分析,采用层次聚类基于10项血清学特征识别分组,并按发病年龄和性别分层。
主要发现
- 聚类1(抗Sm/RNP)与最严重表型相关,浆膜炎发生率更高(P=0.001),皮肤表现更多(P=0.006)。
- 聚类1患者需多种免疫抑制剂(P=0.01),生物制剂使用率最高(P=0.024)。
- 聚类4疾病活动度最低(P=0.004),DORIS缓解率最高(P=0.004)。
- 晚发型SLE患者接受生物制剂显著更少(11.1% vs 35.5%,P<0.001),传统免疫抑制剂更少(68.5% vs 83.2%,P=0.013)。
- 晚发型SLE患者累积器官损伤更重(SDI>0:70.4% vs 52.4%,P=0.015)。
关键数值与推荐
- 基于抗dsDNA、抗Sm、狼疮抗凝物、抗心磷脂、抗B2GP1、低补体血症、直接Coombs试验、抗Ro、抗La和抗RNP共10项血清学特征进行层次聚类。
- 队列以女性为主(84.7%)。
临床怎么用
- 对具抗Sm/RNP血清学特征的患者应考虑强化生物制剂治疗。
- 对晚发型SLE患者需警惕治疗不足导致的器官损伤累积。
- 血清学指导的分层可用于指导先进疗法的选择。
局限性
- 为单中心回顾性横断面分析,样本量327例,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify and analyse distinct subgroups of SLE based on serological and demographic profiles, and to assess their impact on clinical manifestations, disease activity and use of advanced therapies. METHODS: We performed a cross-sectional analysis of a single-centre cohort of 327 SLE patients. Hierarchical cluster analysis was used to identify groups based on 10 serological features: anti-dsDNA, anti-Sm, lupus anti-coagulant, anti-cardiolipin, anti-B2GP1, hypocomplementemia, direct Coombs test, anti-Ro, anti-La and anti-RNP. We further stratified patients by age of onset and sex. RESULTS: The cohort was predominantly female (84.7%). Four serological clusters emerged: Cluster 1 (anti-Sm/RNP), Cluster 2 (aPL), Cluster 3 (anti-Ro/La) and Cluster 4 (dsDNA positive and ENA/aPL scarce). Cluster 1 (anti-Sm/RNP) was associated with the most severe phenotype, with higher rates of serositis (P = 0.001) and cutaneous manifestations (P = 0.006). These patients required multiple immunosuppressants (P = 0.01) and had the highest utilization of biologics (P = 0.024). Conversely, Cluster 4 showed the lowest disease activity (P = 0.004) and highest rates of DORIS remission (P = 0.004). Notably, patients with late-onset SLE received significantly fewer biologics (11.1% vs 35.5%, P < 0.001) and conventional immunosuppressants (68.5% vs 83.2%, P = 0.013), yet they accrued greater cumulative organ damage (SDI >0: 70.4% vs 52.4%, P = 0.015) compared with early-onset patients. CONCLUSION: The anti-Sm/RNP signature identifies a severe, refractory phenotype, potentially necessitating intensified biologic therapy. Late-onset SLE represents a silent risk group, where lower treatment intensity correlates with higher damage accrual, suggesting current management strategies may be insufficient. These findings challenge the standard of care and support the implementation of serology-guided stratification.
引用
- Degen E, Chan CWS, Tascilar K, et al. Use of advanced therapies in systemic lupus erythematosus: a retrospective single-centre analysis based on disease phenotypes. Rheumatology (Oxford). 2026. PMID: 42847663. doi:10.1093/rheumatology/keag441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。